Banner for leaf pages 2

Adalimumab (Humira)

Also known as Humira

Adalimumab (HUMIRA, AbbVie) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to Tumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors. Adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012 by the FDA in the disease's management, it has been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's Disease.

Source: Wikipedia

Estimated Total Cost: $1858.52 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed adalimumab to treat rheumatoid arthritis, crohn disease, psoriasis, and osteoporosis.

What drug interactions are known?

Do not take adalimumab if you are taking any of the following:

Critical Interactions

Significant Interactions

Ajax-loader Loading...